Highest-materiality recent filing
IDEAYA: darovasertib combo meets primary endpoint in mUM; Q2 net loss $112.5M; cash $1.24B
Registrational OptimUM-02 trial met primary endpoint: median PFS 6.9 vs 3.1 months (HR 0.42, p<0.0001); NDA filing underway under RTOR.
IDEAYA holds annual meeting, elects directors, appoints Hata Chairman and Rosen Lead Director
All three Class I director nominees elected: Hata (70.5M for), Hampton (56.7M for), Mackey (70.3M for).
IDEAYA raises $323.6M net in follow-on offering of 7.2M shares and pre-funded warrants
Sold 7,222,225 shares and pre-funded warrants for 5,555,576 shares at $27.00/share public price.
IDEAYA announces clinical collaboration with Roche for PRMT5 + pan-RAS combo in MTAP-deleted PDAC
IDE892 (PRMT5 inhibitor) to be combined with Roche's RG6505 (pan-RAS inhibitor) in MTAP-deleted, RAS-mutant pancreatic cancer.
Darovasertib + crizotinib achieved median PFS 6.9 months vs 3.1 months for investigator's choice (HR=0.42, p<0.0001) by BICR, reducing risk of progression by 58%.
IDEAYA reports positive Phase 2/3 darovasertib trial; Q1 net loss $98.5M, cash $973M
Phase 2/3 OptimUM-02 met primary endpoint: 58% risk reduction in PFS (HR 0.42, p<0.0001), median PFS 6.9 vs 3.1 months.
IDEAYA files new S-3ASR; $156.6M ATM capacity remains under Jefferies agreement
Filed new automatic shelf registration (S-3ASR) to replace expiring June 2026 shelf; effective May 5, 2026.
Darovasertib + crizotinib reduced risk of disease progression by 58% (HR 0.42, p<0.0001) in 1L HLA-A*02:01-negative mUM.
IDEAYA enters clinical collaboration with AstraZeneca for IDE849 + Imfinzi in SCLC
Collaboration to evaluate IDE849 (DLL3 TOP1 ADC) plus AstraZeneca's Imfinzi in extensive-stage SCLC.
IDEAYA expects topline PFS data from darovasertib Phase 2/3 trial by late March 2026
130 required PFS events confirmed by BICR; topline results from OptimUM-02 trial (1L HLA*A2-negative mUM) expected ~last week of March 2026.
IDEAYA posts corporate presentation at JPM 2026; no new material data disclosed in filing
Corporate presentation posted to investor website dated January 12, 2026, for JPM Healthcare Conference.
Topline PFS results from Phase 2/3 OptimUM-02 for darovasertib+crizotinib in 1L HLA*A2-negative mUM expected Q1 2026.
GSK terminates collaboration on IDE275 and IDE705; programs returning to IDEAYA
GSK gave written notice on Dec 9, 2025 to terminate the June 2020 Collaboration, Option and License Agreement.
GSK terminates collaboration; IDEAYA regains IDE275 and IDE705; cash runway unchanged
GSK terminates Collaboration, Option and License Agreement effective 90 days after Dec 4, 2025; programs transferred back to IDEAYA.
IDEAYA reports Q3 net income $119.2M, cash $1.14B; darovasertib partnership with Servier closed
Net income of $119.2M vs Q2 net loss of $77.5M; collaboration revenue $207.8M from Servier license.
IDEAYA reports Phase 2 darovasertib data: median OS 21.1 mo in 1L mUM; 57% eye preservation
Darovasertib + crizotinib in 1L mUM: median OS 21.1 mo (historical ~12 mo), median PFS 7.0 mo, ORR 34%, DCR 90%.
IDE849 (DLL3 ADC) showed 73.2% ORR (52/71) and 47.9% confirmed ORR in SCLC at >=2.4 mg/kg; median PFS 6.7 months.
IDEAYA licenses darovasertib ex-US to Servier for $210M upfront plus milestones up to $320M
Exclusive license to Servier for darovasertib outside the US; all human diagnostic, prophylactic, therapeutic uses.
IDEAYA Q2 net loss $77.5M; cash ~$992M; darovasertib PFS data on track for YE2025
Net loss of $77.5M for Q2 2025 vs $72.2M in Q1 2025; R&D expenses $74.2M, G&A $14.6M.
IDEAYA Biosciences appoints Joshua Bleharski as CFO
Joshua Bleharski, Ph.D. appointed CFO and Principal Financial Officer effective June 26, 2025.
IDEAYA shareholders elect Stein and Morrison; Morrison with 45% withheld votes
Jeffrey L. Stein elected with 69.1M votes for (89.7%); Scott W. Morrison elected with 42.1M for (54.7%), 34.9M withheld.
IDEAYA Q1 2025 net loss $72.2M; cash ~$1.05B funds ops into 2029; darovasertib enrollment >300 pts
Cash, equivalents and securities $1.05B as of March 31, 2025, supporting updated runway into 2029.
Director Susan Kelley to step down from IDEAYA board, move to advisory role
Susan L. Kelley, M.D. will not stand for re-election at the 2025 annual meeting of stockholders.
IDEAYA reports Q4 2024 net loss of $130.3M; cash ~$1.1B, funds operations into at least 2028
Cash, equivalents and marketable securities of ~$1.1B as of Dec 31, 2024, up from $632.6M in 2023.
IDEAYA appoints Joshua Bleharski as CFO, effective May 2025
Joshua Bleharski, Ph.D., age 50, appointed Chief Financial Officer, effective early May 2025.
IDEAYA licenses DLL3 ADC SHR-4849 from Hengrui; total potential payments $1.045B
Exclusive worldwide license (ex-Greater China) for Phase 1 DLL3-targeting Topo-I-payload ADC SHR-4849.
IDEAYA reports Q3 net loss of $51.8M; cash $1.2B; progress in darovasertib and IDE397 trials
Net loss of $51.8M for Q3 2024; R&D expenses $57.2M; G&A $9.7M.
IDEAYA reports 33% ORR in Phase 1 IDE397 in MTAP-deletion urothelial cancer and NSCLC
Overall response rate 33% (1 CR, 8 PR) in 27 evaluable patients; all 9 responses confirmed.
Phase 1 expansion results for IDE397 (MAT2A inhibitor) in MTAP-deletion NSCLC and urothelial cancer to be presented as late-breaker oral on Oct 25.
59% of 49 evaluable patients had >=20% ocular tumor shrinkage; 49% had >=30% shrinkage by product of diameters.
Q2 net loss $52.8M vs $39.6M in Q1; R&D expenses $54.5M, up from $42.8M.
IDEAYA enters option/license deal with Biocytogen for B7H3/PTK7 BsADC; total potential $406.5M
Total potential payments of $406.5M including $100M development/regulatory milestones and single-digit royalties.
IDEAYA Biosciences completes $283.8M public offering of common stock and pre-funded warrants
Offered 8,355,714 common shares and pre-funded warrants for 285,715 shares at $35.00 per share/$34.9999 per warrant.
IDEAYA reports preliminary Q2 cash of $952.7M; sells 922k shares via ATM at ~$40.40
Preliminary cash, cash equivalents & marketable securities of ~$952.7M as of June 30, 2024 (unaudited).
IDEAYA reports 39% ORR in IDE397 Phase 2 monotherapy for MTAP-deletion cancers
Overall response rate 39% (1 CR, 6 PRs by RECIST 1.1) in 18 evaluable MTAP-deletion urothelial cancer and NSCLC patients.
IDEAYA Biosciences CLO Jason Throne resigns effective July 11, 2024
Jason Throne voluntarily resigned as Chief Legal Officer and Secretary.
IDEAYA darovasertib Phase 2 uveal melanoma data: 75% eye saved, 47% median tumor shrinkage
Investigator-sponsored Phase 2: 75% of enucleation patients (9/12) had eye saved (converted to brachytherapy/EBRT) after 6 months.
IDEAYA Biosciences annual meeting results: all four proposals approved by shareholders
Elected Dr. Terry J. Rosen (54.5M for) and Wendy L. Yarno (64.2M for) as Class II directors; 1.8M and 2.2M broker non-votes.
IDEAYA Q1 net loss $39.6M, cash $941M; darovasertib UM data at ASCO, Werner IND on track
Net loss of $39.6M for Q1 2024; cash, equivalents and marketable securities $941.4M, projected to fund operations into 2028.
IDEAYA Enters Clinical Collaboration with Merck to Evaluate IDE161 + KEYTRUDA in Endometrial Cancer
Phase 1 trial will test IDE161 (PARG inhibitor) + KEYTRUDA in MSI-high and MSS endometrial cancer.
IDYA reports Q4 net loss $34M, cash $632.6M; multiple 2024 milestones
Cash $632.6M at Dec 31, 2023; Jan 2024 ATM raised ~$352M gross ($342.3M net); runway into 2028.
IDEAYA raises $126.9M net via ATM sale of 3.12M shares at ~$41.50 each
Sold 3,119,866 shares at weighted avg price of $41.50; net proceeds ~$126.9M.
IDEAYA Biosciences enters $350M at-the-market stock offering with Jefferies
Up to $350M in common stock may be sold from time to time through Jefferies as sales agent.
IDEAYA Biosciences sells 1.56M shares for $57M net under ATM, exhausting $250M facility
Sold 1,561,735 shares at ~$37.60/share, net proceeds ~$57.0M under June 2023 ATM with Jefferies.
IDEAYA raises ~$158.9M via ATM equity offering; shares sold at ~$35.97 avg price
Sold 4,553,781 shares during Jan 4-11, 2024 under ATM agreement with Jefferies.
IDEAYA and Gilead will evaluate IDE397 (MAT2A inhibitor) plus Trodelvy (Trop-2 ADC) in MTAP-deletion bladder cancer.
IDEAYA signs lease for 6,000 sq ft San Diego office; base rent $1.58M over ~4.25 yrs
Leased 6,000 sq ft at 11710 El Camino Real, San Diego, replacing and expanding current office.
IDEAYA Q3 cash $511M, darovasertib shows 42% ORR in 1L HLA-A2(-) MUM; registrational trial ongoing
Cash, cash equivalents and marketable securities of $511.1M as of Sep 30, 2023; plus $134.7M net proceeds from follow-on and $10M GSK milestone receivable.
IDEAYA completes $134.7M public offering of stock and pre-funded warrants
Offered 5,797,872 shares of common stock and 319,150 pre-funded warrants at $23.50/share and $23.4999/warrant.
IDEAYA reports preliminary $511M cash; ATM facility update with $222.5M remaining
Preliminary cash, cash equivalents and marketable securities of $511.1M as of Sept 30, 2023 (unaudited, subject to change).
Dr. Kelley will resign from the Board at the end of her current term, which will conclude immediately after the Annual Meeting.
On February 10, 2025, the Board of Directors (the “Board”) of IDEAYA Biosciences, Inc. (the “Company”) appointed Joshua Bleharski, Ph.D. as Chief Financial Officer of the Company, effective early May 2025
On June 21, 2024, Jason Throne informed IDEAYA Biosciences, Inc. (the “Company”) of his voluntary resignation from his positions as Chief Legal Officer and Secretary of the Company.
On September 21, 2023, Paul A. Stone informed IDEAYA Biosciences, Inc. (the “Company”), of his voluntary resignation from his position as Chief Financial Officer of the Company. Mr. Stone’s resignation will be effective as of November 10, 2023
appointed Andres Ruiz Briseno as Principal Accounting Officer of the Company, effective July 1, 2023
On April 6, 2022, IDEAYA Biosciences, Inc. (the “Company”) announced the appointment of Catherine J. Mackey, Ph.D. as a member of its Board of Directors (the “Board”), effective April 5, 2022.
Max materiality 0.85 · Median 0.68 · Most common event other_material